Educational only. Not medical advice. Invite-only research preview.No PHI. Do not share patient names or identifying information (HIPAA).
MytoIntelligence
All targets

Molecular target

Protein Tyrosine Kinase Signaling (broad)

Also: PTK, Tyrosine Kinase · id TYROSINE_KINASE

Receptor and non-receptor protein tyrosine kinases — a broad proliferative-signaling node targeted by tyrosine-kinase-inhibitor oncology drugs. Numerous flavonoids and polyphenols (quercetin, EGCG, genistein, luteolin, apigenin) have been investigated as kinase modulators in preclinical research.

14 drugs act here1 plant reach it via their compounds

Educational use only. This page summarizes published research and traditional-use records for educational purposes. It does not diagnose, treat, cure, or prevent any disease. Do not start, stop, or change medications based on this information. Discuss any decisions about therapies — pharmaceutical or botanical — with a qualified clinician who knows your medical history.

No PHI / HIPAA notice: Do not share Protected Health Information (PHI) of any patient on this site — including names, dates of birth, addresses, MRNs, or any identifying information. Use abstract case framing only. Sharing PHI with non-covered entities risks HIPAA violation regardless of platform capability.

Pharmaceutical agents

Drugs that act on Protein Tyrosine Kinase Signaling (broad)

These medications have Protein Tyrosine Kinase Signaling (broad) among their molecular targets. Sharing a target is a mechanistic relationship — it does not make any plant below an alternative to, or substitute for, these drugs.

Botanical connections

Plants whose compounds act on Protein Tyrosine Kinase Signaling (broad)

Each plant below contains a named compound documented to act on Protein Tyrosine Kinase Signaling (broad). The compound and the reason for the connection are shown on every edge — a shared mechanism, not a therapeutic equivalence.

  • GenisteinIsoflavone

    Beyond estrogen-receptor binding, genistein is a classically characterized protein-tyrosine-kinase inhibitor and has been studied for anti-angiogenic (VEGF) activity in preclinical cancer models. Research only — not a treatment claim.

A shared molecular target shows how a botanical and a drug relate mechanistically. It is not evidence that one can replace the other. Educational summary only — discuss any medication decision with your clinician.